pSivida Corp.  

(Public, NASDAQ:PSDV)   Watch this stock  
Find more results for PSDV
0.00 (0.00%)
Oct 20 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.20 - 2.31
52 week 2.18 - 5.81
Open 2.27
Vol / Avg. 119,692.00/114,162.00
Mkt cap 76.25M
P/E     -
Div/yield     -
EPS -0.68
Shares 34.18M
Beta 1.67
Inst. own 38%
Dec 12, 2016
pSivida Corp Annual Shareholders Meeting - 10:00AM EST - Add to calendar
Dec 2, 2016
pSivida Corp Annual Shareholders Meeting (Estimated) - 10:00AM EST - Add to calendar
Nov 3, 2016
Q1 2017 pSivida Corp Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Sep 27, 2016
pSivida Corp at Ladenburg Thalmann Healthcare Conference
Sep 12, 2016
Q4 2016 pSivida Corp Earnings Call
Sep 12, 2016
Q4 2016 pSivida Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2016
Net profit margin -2100.99% -1330.06%
Operating margin -2123.68% -1344.07%
EBITD margin - -1288.03%
Return on average assets -75.59% -67.35%
Return on average equity -108.02% -97.39%
Employees 20 -
CDP Score - -


480 Pleasant St Ste B300
WATERTOWN, MA 02472-2468
United States - Map
+1-617-9265000 (Phone)
+1-617-9265050 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


pSivida Corp. develops drug delivery products primarily for the treatment of chronic eye diseases. The Company operates through the biotechnology sector segment. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert. Medidur is designed to treat chronic non-infectious uveitis affecting the posterior segment of the eye (posterior segment uveitis). ILUVIEN is an injectable micro-insert that provides treatment of DME from a single injection. Retisert is an implant that provides treatment of posterior segment uveitis. Its product development program is focused on utilizing its two technology platforms, Durasert and Tethadur, to deliver drugs and biologics to treat chronic diseases.

Officers and directors

David J. Mazzo Ph.D. Independent Chairman of the Board
Age: 58
Bio & Compensation  - Reuters
Nancy S. Lurker President, Chief Executive Officer, Director
Age: 58
Bio & Compensation  - Reuters
Leonard S. Ross Vice President - Finance, Principal Financial Officer
Age: 65
Bio & Compensation  - Reuters
Lori Freedman Vice President - Corporate Affairs, General Counsel, Company Secretary
Age: 48
Bio & Compensation  - Reuters
Jay S. Duker M.D. Director
Bio & Compensation  - Reuters
James J. Barry Ph.D. Independent Director
Age: 56
Bio & Compensation  - Reuters
Douglas Evan Godshall M.B.A. Independent Director
Age: 50
Bio & Compensation  - Reuters
Michael W. Rogers Independent Director
Age: 56
Bio & Compensation  - Reuters